- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03627910
Pressure Ulcers in Patients Receiving Enteral Nutrition Therapy and Their Relationship With Gut Microbiota
February 4, 2021 updated by: Fondazione Don Carlo Gnocchi Onlus
Pressure Ulcers in Patients Receiving Enteral Nutrition Therapy. What is the Relationship With Gut Microbiota?
Participants will be randomly assigned to the experimental group where they will be given enteral nutrition formula rich in zinc and arginine plus a symbiotic (Probinul- Ca.Di.GROUP S.r.l.) once a day for 90 days or the control group where they will receive only the enteral nutrition formula rich in zinc and arginine.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Participants belonging to both experimental and control group will be evaluated at admission (T0), 45 days after admission (T45) and at the end of the study (T90, 90 days after admission).
At each time point patients' nutritional status will be determined and the following biochemical parameters will be investigated: lymphocyte count, total proteins, protidogram, prealbumin, transferrin, vascular endothelial growth factor (VEGF), Platelet-derived growth factor (PDGF), beta transforming growth factor (TGF-beta). Analysis of fecal DNA will be also performed to characterize the gut microbiota.
In addition, at the baseline and at T45 participants will be administered the Braden scale for predicting pressure sore risk.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Chiara Francesca Gheri, Dr.
- Phone Number: 00393281512053
- Email: cgheri@dongnocchi.it
Study Contact Backup
- Name: Maria Luisa Eliana Luisi, Dr.
- Phone Number: 3356305688
- Email: mluisi@dongnocchi.it
Study Locations
-
-
-
Firenze, Italy, 50143
- Recruiting
- Fondazione Don Carlo Gnocchi
-
Contact:
- Chiara Francesca Gheri, MD
- Phone Number: 00393281512053
- Email: cgheri@dongnocchi.it
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with enteral nutrition therapy
- Presence of pressure ulcers
- Previous antibiotic therapy
Exclusion Criteria:
- nutrition per os
- absence of pressure ulcers
- absence of previous antibiotic therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group
Participants assigned to the treatment group will be administered a commercial symbiotic (Probinul Ca.Di.GROUP S.r.l.) for the entire duration of the study (90 days) plus an enteral nutrition formula rich in zinc and arginine
|
Feed supplementation
Feed supplementation
|
Active Comparator: Control group
Control group will be administered only an enteral nutrition formula rich in zinc and arginine
|
Feed supplementation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of Transforming Growth Factor β (TGF-β1), Epidermal Growth Factor (EGF) and Vascular Endothelial Growth Factor (VEGF)
Time Frame: 90 days after the fist time point (baseline assessment)
|
Human EGF, human VEGF/human TGF-β1 will be measured on aliquots (20 μl) of plasma using Quantikine® ELISA Human Immunoassay (R&D System, Abingdon, UK), following the manufacturer's protocol.
The quantitative sandwich enzyme immunoassay technique will be used.
A monoclonal antibody specific for human EGF/human VEGF, is pre-coated onto a microplate.
For TGF -β1 assay latent TGF-β1 must be activated before test, following a procedure of acidification and then neutralization to pH 7.2-7.6.
Standards and samples are pipetted into the wells and EGF or VEGF present is bound by the immobilized antibody.
After washing away unbound substances, an enzyme-linked polyclonal antibody specific for human EGF/human VEGF is added to the wells.
After removing any unbound antibody-enzyme reagent, a substrate solution is added and colour develops in proportion to the amount of EGF bound.
Colour development is stopped, and colour intensity measured.
Tests will be performed in triplicates for each sample.
|
90 days after the fist time point (baseline assessment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monitoring modification of gut microbiota through DNA extraction and quantification
Time Frame: 45 days after the fist time point (baseline assessment) and 90 days after the fist time point (baseline assessment)
|
Total DNA will be extracted in triplicate from all the fecal samples by following the QIAamp DNA Stool Mini Kit instructions (Qiagen) and quantified with a Qubit® 2.0 fluorometer (Invitrogen, USA).
Molecular weight and fragment length of DNA will be checked on 1.5 % agarose gel; the yield will be calculated as µg DNA/g feces.
Quantitative PCR (qPCR) assays will be conducted using the specific primers rpoB1, rpoB1o and rpoB2 that generate amplicons of 250-bp, on 10 ng DNA templates for all the samples.
Amplification will be carried out and three simultaneous replicates will be carried out for each of analyzed sample.
|
45 days after the fist time point (baseline assessment) and 90 days after the fist time point (baseline assessment)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Maria Luisa Eliana Luisi, MD, Don Gnocchi Foundation, Italy
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med. 2016 Dec 15;375(24):2369-2379. doi: 10.1056/NEJMra1600266. No abstract available.
- Valentini L, Pinto A, Bourdel-Marchasson I, Ostan R, Brigidi P, Turroni S, Hrelia S, Hrelia P, Bereswill S, Fischer A, Leoncini E, Malaguti M, Blanc-Bisson C, Durrieu J, Spazzafumo L, Buccolini F, Pryen F, Donini LM, Franceschi C, Lochs H. Impact of personalized diet and probiotic supplementation on inflammation, nutritional parameters and intestinal microbiota - The "RISTOMED project": Randomized controlled trial in healthy older people. Clin Nutr. 2015 Aug;34(4):593-602. doi: 10.1016/j.clnu.2014.09.023. Epub 2014 Oct 8.
- Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021 Jan;19(1):55-71. doi: 10.1038/s41579-020-0433-9. Epub 2020 Sep 4.
- Munoz N, Posthauer ME, Cereda E, Schols JMGA, Haesler E. The Role of Nutrition for Pressure Injury Prevention and Healing: The 2019 International Clinical Practice Guideline Recommendations. Adv Skin Wound Care. 2020 Mar;33(3):123-136. doi: 10.1097/01.ASW.0000653144.90739.ad.
- Luisi MLE, Lucarini L, Biffi B, Rafanelli E, Pietramellara G, Durante M, Vidali S, Provensi G, Madiai S, Gheri CF, Masini E, Ceccherini MT. Effect of Mediterranean Diet Enriched in High Quality Extra Virgin Olive Oil on Oxidative Stress, Inflammation and Gut Microbiota in Obese and Normal Weight Adult Subjects. Front Pharmacol. 2019 Nov 15;10:1366. doi: 10.3389/fphar.2019.01366. eCollection 2019.
- Cereda E, Neyens JCL, Caccialanza R, Rondanelli M, Schols JMGA. Efficacy of a Disease-Specific Nutritional Support for Pressure Ulcer Healing: A Systematic Review and Meta-Analysis. J Nutr Health Aging. 2017;21(6):655-661. doi: 10.1007/s12603-016-0822-y.
- Ammons MC, Morrissey K, Tripet BP, Van Leuven JT, Han A, Lazarus GS, Zenilman JM, Stewart PS, James GA, Copie V. Biochemical association of metabolic profile and microbiome in chronic pressure ulcer wounds. PLoS One. 2015 May 15;10(5):e0126735. doi: 10.1371/journal.pone.0126735. eCollection 2015.
- Wang X, Dong Y, Han X, Qi XQ, Huang CG, Hou LJ. Nutritional support for patients sustaining traumatic brain injury: a systematic review and meta-analysis of prospective studies. PLoS One. 2013;8(3):e58838. doi: 10.1371/journal.pone.0058838. Epub 2013 Mar 19.
- Teno JM, Gozalo P, Mitchell SL, Kuo S, Fulton AT, Mor V. Feeding tubes and the prevention or healing of pressure ulcers. Arch Intern Med. 2012 May 14;172(9):697-701. doi: 10.1001/archinternmed.2012.1200.
- Ohura T, Nakajo T, Okada S, Omura K, Adachi K. Evaluation of effects of nutrition intervention on healing of pressure ulcers and nutritional states (randomized controlled trial). Wound Repair Regen. 2011 May-Jun;19(3):330-6. doi: 10.1111/j.1524-475X.2011.00691.x.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 11, 2017
Primary Completion (Anticipated)
June 30, 2021
Study Completion (Anticipated)
January 31, 2022
Study Registration Dates
First Submitted
August 1, 2018
First Submitted That Met QC Criteria
August 8, 2018
First Posted (Actual)
August 14, 2018
Study Record Updates
Last Update Posted (Actual)
February 9, 2021
Last Update Submitted That Met QC Criteria
February 4, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ulcere1_FDG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malnutrition
-
HAN University of Applied SciencesFrieslandCampina; HAS Hogeschool; Centre of Expertise Food (CoE Food); SligroCompletedMalnutrition; Protein | Protein MalnutritionNetherlands
-
UNICEFSave the ChildrenCompletedSevere MalnutritionCongo, The Democratic Republic of the
-
International Centre for Diarrhoeal Disease Research...GlaxoSmithKline; Stanford UniversityCompletedMalnutrition | Malnutrition in Children | Child MalnutritionBangladesh
-
University of Nove de JulhoUnknownMalnutrition, ChildBrazil
-
International Centre for Diarrhoeal Disease Research...UNICEFNot yet recruitingMalnutrition SevereBangladesh
-
Action Against Hunger USAUniversity of Washington; Ethiopian Public Health InstituteNot yet recruitingModerate Acute Malnutrition | Severe Acute Malnutrition
-
Academy of Nutrition and DieteticsHartford Hospital; University of New Mexico; Meals on Wheels Central TexasNot yet recruiting
-
Diego MorettiSwiss Federal Institute of Technology; Wageningen University and Research; St... and other collaboratorsCompletedMalnutrition; ProteinSwitzerland
-
International Centre for Diarrhoeal Disease Research...CompletedProtein MalnutritionBangladesh
-
Microbiome Health Research InstituteUniversity of Cape TownTerminatedModerate Acute Malnutrition | Severe Acute MalnutritionSouth Africa
Clinical Trials on symbiotic
-
Mashhad University of Medical SciencesUnknown
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...University of Bari Aldo MoroCompletedHealthy | Chronic Kidney DiseasesItaly
-
Conselho Nacional de Desenvolvimento Científico...CompletedSigns and Symptoms, Digestive | Dyslipidemia | HIV | Dietary ModificationBrazil
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...University of Bari Aldo MoroCompleted
-
Federal University of Minas GeraisCompletedHead and Neck Cancer | Nutrition Therapy | SynbioticsBrazil
-
Peking Union Medical College HospitalNot yet recruiting
-
Zeynep Kamil Maternity and Pediatric Research and...Completed
-
Hospital de Clinicas de Porto AlegreUnknownColorectal Cancer | Surgical Site InfectionBrazil
-
National University Hospital, SingaporeNational University of SingaporeNot yet recruitingCardiovascular Diseases | Metabolic Syndrome | Non-Alcoholic Fatty Liver Disease
-
University of Sao PauloGanep Human NutritionUnknown